An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
NCT ID: NCT00335374
Last Updated: 2009-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
202 participants
INTERVENTIONAL
2007-08-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
NCT00332917
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
NCT00407095
SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT00269516
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
NCT00335166
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
NCT00974974
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Pardoprunox
12 -42 mg
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pardoprunox
12 -42 mg
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
419
Birmingham, Alabama, United States
413
Oceanside, California, United States
408
Oxnard, California, United States
422
New Haven, Connecticut, United States
403
Boca Raton, Florida, United States
411
Sarasota, Florida, United States
421
Augusta, Georgia, United States
410
Fort Wayne, Indiana, United States
417
Lexington, Kentucky, United States
405
Boston, Massachusetts, United States
420
Boston, Massachusetts, United States
406
Minneapolis, Minnesota, United States
412
Raleigh, North Carolina, United States
Site 402
Dayton, Ohio, United States
303
Bedford Park, , Australia
304
Cheltenham, , Australia
301
Concord, , Australia
Site 300
East Gosford, , Australia
302
Westmead, , Australia
315
Kralove, , Czechia
313
Olomouc, , Czechia
310
Ostrava, , Czechia
314
Ostrava, , Czechia
312
Pardubice, , Czechia
311
Pilsen, , Czechia
320
Tallinn, , Estonia
321
Tartu, , Estonia
332
Bochum, , Germany
331
Göttingen, , Germany
329
Heidelberg, , Germany
330
Leipzig, , Germany
328
Lübeck, , Germany
326
Wiesbaden, , Germany
338
Bangalore, , India
339
Hyderabaad, , India
337
Kerala, , India
336
Mumbai, , India
340
Mumbai, , India
348
Grosseto, , Italy
346
Lido di Camaiore, , Italy
344
Pescara, , Italy
343
Roma, , Italy
345
Roma, , Italy
428
Kaunas, , Lithuania
427
Vilnius, , Lithuania
429
Vilnius, , Lithuania
355
Kelantan, , Malaysia
357
Kuala Lumpur, , Malaysia
356
Pulau Pinang, , Malaysia
361
's-Hertogenbosch, , Netherlands
364
Eindhoven, , Netherlands
360
Groningen, , Netherlands
362
Groningen, , Netherlands
373
Gdansk, , Poland
371
Kalisz, , Poland
369
Katowice, , Poland
365
Krakow, , Poland
368
Leszno, , Poland
366
Lublin, , Poland
370
Mosina, , Poland
376
Coimbra, , Portugal
375
Lisbon, , Portugal
377
Cape Town, , South Africa
378
Cape Town, , South Africa
380
Gauteng, , South Africa
381
Pretoria, , South Africa
379
Sandton, , South Africa
388
Hualien City, , Taiwan
387
Kaohsiung City, , Taiwan
389
Kaohsiung Hsien, , Taiwan
386
Kwei-Shan, , Taiwan
385
Taipei, , Taiwan
391
Bangkok, , Thailand
393
Bangkok, , Thailand
394
Ubonratchathani, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-000859-18
Identifier Type: -
Identifier Source: secondary_id
S308.3.008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.